Literature DB >> 28359232

Identification and Characterization of a Chemical Compound that Inhibits Methionyl-tRNA Synthetase from Pseudomonas aeruginosa.

Sara Robles1, Yanmei Hu1, Tahyra Resto1, Frank Dean1, James M Bullard1.   

Abstract

BACKGROUND: Pseudomonas aeruginosa is an opportunistic pathogen problematic in causing nosocomial infections and is highly susceptible to development of resistance to multiple antibiotics. The gene encoding methionyl-tRNA synthetase (MetRS) from P. aeruginosa was cloned and the resulting protein characterized.
METHODS: MetRS was kinetically evaluated and the KM for its three substrates, methionine, ATP and tRNAMet were determined to be 35, 515, and 29 μM, respectively. P. aeruginosaMetRS was used to screen two chemical compound libraries containing 1690 individual compounds.
RESULTS: A natural product compound (BM01C11) was identified that inhibited the aminoacylation function. The compound inhibited P. aeruginosa MetRS with an IC50 of 70 μM. The minimum inhibitory concentration (MIC) of BM01C11 was determined against nine clinically relevant bacterial strains, including efflux pump mutants and hypersensitive strains of P. aeruginosa and E. coli. The MIC against the hypersensitive strain of P. aeruginosa was 16 μg/ml. However, the compound was not effective against the wild-type and efflux pump mutant strains, indicating that efflux may not be responsible for the lack of activity against the wild-type strains. When tested in human cell cultures, the cytotoxicity concentration (CC50) was observed to be 30 μg/ml. The compound did not compete with methionine or ATP for binding MetRS, indicating that the mechanism of action of the compound likely occurs outside the active site of aminoacylation.
CONCLUSION: An inhibitor of P. aeruginosa MetRS, BM01C11, was identified as a flavonoid compound named isopomiferin. Isopomiferin inhibited the enzymatic activity of MetRS and displayed broad spectrum antibacterial activity. These studies indicate that isopomiferin may be amenable to development as a therapeutic for bacterial infections. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Protein synthesis; Pseudomonas.; antibiotics; drug discovery; in vitro screening; tRNA aminoacylation

Mesh:

Substances:

Year:  2017        PMID: 28359232      PMCID: PMC5788008          DOI: 10.2174/1570163814666170330100238

Source DB:  PubMed          Journal:  Curr Drug Discov Technol        ISSN: 1570-1638


  30 in total

Review 1.  Pseudomonas aeruginosa: all roads lead to resistance.

Authors:  Elena B M Breidenstein; César de la Fuente-Núñez; Robert E W Hancock
Journal:  Trends Microbiol       Date:  2011-06-12       Impact factor: 17.079

2.  Antimicrobial activity of Inga fendleriana extracts and isolated flavonoids.

Authors:  Luisa Pistelli; Alessandra Bertoli; Cecilia Noccioli; Jeanette Mendez; Rosa Anna Musmanno; Tiziana Di Maggio; Grazietta Coratza
Journal:  Nat Prod Commun       Date:  2009-12       Impact factor: 0.986

3.  Purification of Escherichia coli DNA polymerase III holoenzyme.

Authors:  M G Cull; C S McHenry
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

4.  Partition of tRNA synthetases into two classes based on mutually exclusive sets of sequence motifs.

Authors:  G Eriani; M Delarue; O Poch; J Gangloff; D Moras
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

5.  Variable sensitivity to bacterial methionyl-tRNA synthetase inhibitors reveals subpopulations of Streptococcus pneumoniae with two distinct methionyl-tRNA synthetase genes.

Authors:  Daniel R Gentry; Karen A Ingraham; Michael J Stanhope; Stephen Rittenhouse; Richard L Jarvest; Peter J O'Hanlon; James R Brown; David J Holmes
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

6.  Activation of methionine by Escherichia coli methionyl-tRNA synthetase.

Authors:  G Ghosh; H Pelka; L H Schulman; S Brunie
Journal:  Biochemistry       Date:  1991-10-08       Impact factor: 3.162

Review 7.  Mupirocin resistance.

Authors:  Jean B Patel; Rachel J Gorwitz; John A Jernigan
Journal:  Clin Infect Dis       Date:  2009-09-15       Impact factor: 9.079

8.  Outer membrane permeability in Pseudomonas aeruginosa: comparison of a wild-type with an antibiotic-supersusceptible mutant.

Authors:  B L Angus; A M Carey; D A Caron; A M Kropinski; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

9.  Mapping of the zinc binding domain of Escherichia coli methionyl-tRNA synthetase.

Authors:  D Fourmy; T Meinnel; Y Mechulam; S Blanquet
Journal:  J Mol Biol       Date:  1993-06-20       Impact factor: 5.469

10.  Brucella melitensis Methionyl-tRNA-Synthetase (MetRS), a Potential Drug Target for Brucellosis.

Authors:  Kayode K Ojo; Ranae M Ranade; Zhongsheng Zhang; David M Dranow; Janette B Myers; Ryan Choi; Steve Nakazawa Hewitt; Thomas E Edwards; Douglas R Davies; Donald Lorimer; Stephen M Boyle; Lynn K Barrett; Frederick S Buckner; Erkang Fan; Wesley C Van Voorhis
Journal:  PLoS One       Date:  2016-08-08       Impact factor: 3.240

View more
  3 in total

Review 1.  Progress and challenges in aminoacyl-tRNA synthetase-based therapeutics.

Authors:  Christopher S Francklyn; Patrick Mullen
Journal:  J Biol Chem       Date:  2019-01-22       Impact factor: 5.157

2.  Dual-targeted hit identification using pharmacophore screening.

Authors:  Galyna P Volynets; Sergiy A Starosyla; Mariia Yu Rybak; Volodymyr G Bdzhola; Oksana P Kovalenko; Vasyl S Vdovin; Sergiy M Yarmoluk; Michail A Tukalo
Journal:  J Comput Aided Mol Des       Date:  2019-11-06       Impact factor: 3.686

3.  Dual-target inhibitors of mycobacterial aminoacyl-tRNA synthetases among N-benzylidene-N'-thiazol-2-yl-hydrazines.

Authors:  Oksana P Kovalenko; Galyna P Volynets; Mariia Yu Rybak; Sergiy A Starosyla; Olga I Gudzera; Sergiy S Lukashov; Volodymyr G Bdzhola; Sergiy M Yarmoluk; Helena I Boshoff; Michael A Tukalo
Journal:  Medchemcomm       Date:  2019-11-28       Impact factor: 3.597

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.